

Freedom of Information Request: Our Reference CTMUHB_232_22

You asked:

I would be grateful if you would please answer the following questions concerning antifungal treatment within your organisation.

1) What is the number of patients in the last 12 months treated with the following product lines:

- A) anidulafungin**
- B) caspofungin**
- C) micafungin**

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

However, in order to fulfil our obligation under Section 16 of the Act to provide advice and assistance, we are able to provide the number of issues. Therefore, please see provided below a table populated with the data that Medicines Management are able to provide in relation to your request.

The period relates to June 2021 to May 2022 the latest 12 months available.

Secondary Care		
Medicine	Pack Size	No Of Issues
ANIDULAFUNGIN 100 mg Intravenous Infusion	1 Vial Pack	12
CASPOFUNGIN 50 mg Intravenous Infusion	1 Vial Pack	587
CASPOFUNGIN 70 mg Intravenous Infusion	1 Vial Pack	477
MICAFUNGIN (all products)	1 Vial Pack	0

2) What is the split of indication over the last 12 months for the following product lines:

- A) anidulafungin**
- B) caspofungin**
- C) micafungin**

Please see response to question 1.

3) For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2) list the average length of treatment time.

Please see response to question 1.